Why faster trials make participant understanding more important than ever
July 15, 2026 | Informed Consent, clinical trials, communication
As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.
“I was confused, didn’t understand half of what he was saying.” The clinician’s reply? “You’ll only retain 2% of what’s discussed.” Then they carried on. They didn’t go back.*
That isn’t how anyone should describe the conversation that determines whether they join a clinical trial. Regulatory reforms are removing unnecessary delays from study approval and start-up, but there’s one part of the process that can’t be compressed: ensuring people genuinely understand what they’re agreeing to.
Longer forms, same confusion
When consent comes up, the instinct is to add more: more detail, more pages, more risks spelled out. The result is documents that are comprehensive, yet largely unread.
One participant, three infusions into a cancer trial, put it plainly: “The list of potential side effects goes on for many pages. Before I could give informed consent, the risks were laid out in exacting detail. It’s hard to stay alert.”*
Patients who go looking for answers often come away with more questions. “I spent a night searching the internet and found nothing useful,” one wrote, “just terrifying statistics and medical jargon written for doctors.”*
These people weren’t asking for less information – they were asking for information they could actually understand. Because disclosure alone isn’t the same as understanding.
Consent is a conversation, not a signature
The problem isn’t always the consent form itself. Sometimes it’s what happens around it. A research coordinator, describing their own site, said the doctor “always pushes for them to sign the consent form without fully understanding the trial,” on the logic that “they’ll learn more as time goes on.” And if a participant asks to take the form home to read, or talk it over with their GP? That’s “looked at as a bad thing, since we might lose the patient.”*
That’s understandable when recruitment timelines are under pressure. But it’s also where informed consent can quietly become a process of collecting signatures rather than building understanding.
People need time to reflect, ask questions, involve family members or speak to healthcare professionals they trust. A signature doesn’t demonstrate understanding. A conversation does.
Clearer isn’t simpler
The goal of informed consent isn’t simply to disclose every possible piece of information. It’s to present information in a way people can understand, use, and act on – using plain language, structuring information logically, introducing visuals where they genuinely aid understanding, and layering information so participants can explore topics in more depth at their own pace.
And it has to work for everyone a trial hopes to reach: older participants, people with lower health literacy, caregivers deciding alongside a patient, and anyone moving between an app and a face-to-face conversation. None of that is a special accommodation. It’s just consent that works.
Why this matters more as trials speed up
Regulatory reforms such as Operation TrialBlazer, the EU Clinical Trials Regulation and the MHRA’s changes around proportionate, risk-based review are all designed to make clinical research more efficient, with faster timelines. That’s good news for patients waiting for new treatments.
Speed may shorten timelines, but it can’t shorten the responsibility to ensure genuine understanding. When people don’t fully understand what they’re joining, uncertainty doesn’t disappear after enrolment. It can resurface later as hesitation, withdrawal, missed assessments or poorer engagement throughout the study. Those challenges affect participant experience, recruitment, retention and ultimately the quality of the data a trial generates.
As trials become faster, understanding – not disclosure – becomes the measure of good consent.
Let’s talk
Clearer consent. Information people can actually use. Materials built for the full range of participants. If your study is picking up pace and you want the people in it to understand what they’re joining – and stay – let’s talk.
*We searched our index of patient and participant discussion for where people describe consenting to, or trying to understand, a clinical trial. The quotes are real, lightly edited for length, with identifying details removed. It’s a self-selected, anonymous source – illustrative, not statistically representative – but it shows, in patients’ own words, where consent is and isn’t working.
References
- US Department of Health and Human Services. Press release. Available here (accessed July 2026).
- Regulation (EU) No 536/2014 of the European Parliament and of the Council on clinical trials on medicinal products for human use (Clinical Trials Regulation).
- Health Research Authority. Clinical trials regulation reform. Available here (accessed July 2026).
- Health Research Authority. Informing participants and seeking consent. Available here (accessed July 2026).
- NHS England. Inclusive digital healthcare: a framework for NHS action on digital inclusion. Available here (accessed July 2026).
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
Clinical trial considerations: Why diversity matters…
Diversity in clinical trials is crucial for understanding diseases and developing new treatments. Here’s why diversity matters…
Clinical trial considerations: Why digital matters…
Digital technology in healthcare is rapidly evolving. In this blog we delve into how digital solutions can help improve patient experience within clinical trials.
Clinical trials explained: Why imagery matters…
Recruiting patients for clinical trials is one of pharma’s greatest challenges. Imagery is a great way to connect with people on an emotional level and forms a big part the…
Clinical trials explained: Why health literacy matters…
Clinical trial recruitment can be a challenge. By applying the principles of health literacy to all materials, we can support people to make an informed choice about whether to take…
Clinical trials explained: Why iconography matters…
Icons serve as a useful form of alternative communication. We spend a lot of time developing icons for healthcare communications. Find out how we use iconography to elevate clinical trial…
Cuttsy+Cuttsy appoints Harriet Karia as Managing Director
Cuttsy+Cuttsy is pleased to announce the appointment of Harriet Karia as its first Managing Director.
Using generative AI in healthcare comms – our promise to our clients
It’s safe to say one of the hottest topics of 2023 has been ChatGPT and the launch of other Generative AI-driven applications. So, we’re sharing our promises, so that when…
Clinical trials explained: Why colour matters…
Colour can be used to emphasise mood, evoke emotions, and determine first impressions of a brand. Find how to use colour effectively in your next clinical trial campaign.
Clinical trials explained: Why branding matters…
With nearly a decade’s experience supporting clinical trials, find out why we think humanising trials through design is so important.
DPHARM2023 – Five key themes impacting clinical trials today
Throughout three fascinating days of conference, some key themes emerged that are impacting study teams and the effectiveness of their clinical trials on a daily basis.